Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 02/09/2012) - The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor.
Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
(Posted: 02/01/2012) - Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.
Late Effects May Not Warrant Using Radiation to Treat Early-Stage Hodgkin Lymphoma
(Posted: 12/22/2011) - Patients with early-stage Hodgkin lymphoma who were treated with multidrug chemotherapy alone were more likely to be alive 12 years later than patients who received treatment that included radiation therapy, according to findings from a phase III clinical trial.
Combination Therapy Shows Promise for Treating Advanced Breast Cancer
(Posted: 12/21/2011) - Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.
New Therapies Offer Valuable Options for Patients with Melanoma
(Posted: 07/19/2011, Updated: 12/07/2011) - Two phase III clinical trials of new therapies for patients with metastatic melanoma presented in June at the 2011 ASCO conference confirmed that the molecularly targeted agent vemurafenib and the immunotherapy agent ipilimumab (Yervoy™) offer valuable new options for a disease in which effective treatments have been lacking.